Eton Pharmaceuticals, Inc. ETON Hemangeol — Other Commitment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherCommitment.
The source filing: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:15 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001437749-26-009059
In February 2026, the Company entered into a license agreement with Pierre Fabre Medicament Sas (“Pierre Fabre”) for the exclusive rights to Hemangeol®, a product used for the treatment of proliferating infantile hermangioma. Under of the terms of the license agreement, the Company paid $14,000 and will also purchase approximately $1,500 of inventory. The Company will also purchase approximately $700 in additional inventory in May 2026. The Company will pay royalties to Pierre Fabre of 8.0% on net sales of Hemangeol®.
Item 1A. Risk Factors
FAQ
- What is Eton Pharmaceuticals, Inc.'s hemangeol — other commitment?
- Eton Pharmaceuticals, Inc. (ETON) reported hemangeol — other commitment of $700K in Q1 2026.
- What does hemangeol — other commitment mean?
- This metric captures miscellaneous contractual obligations or future financial commitments related to the commercialization of a specific product that do not fall under standard royalty or acquisition categories. It may include milestone payments, minimum purchase requirements, or other performance-based obligations. It is essential for assessing the long-term financial liabilities associated with a product's lifecycle.
Ask your AI about Eton Pharmaceuticals, Inc.'s hemangeol — other commitment.
Connect your AI assistant and compare it to peers, right in your chat.
